Hodgkin Lymphoma Treatment Regimens

Share this content:
SEE BELOW THE CHART TO SEE DRUG MONOGRAPHS FOR LEUKEMIAS, LYMPHOMAS, AND OTHER HEMATOLOGIC CANCERS.



HODGKIN LYMPHOMA TREATMENT REGIMENS

Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment.

Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies.

These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

(Revised 4/2018)

© 2018 by Haymarket Media, Inc.

Classical Hodgkin Lymphoma1

Note: All recommendations are Category 2A unless otherwise indicated.

Primary Treatment

Stage IA, IIA Favorable (No Bulky Disease, <3 Sites of Disease, ESR <50, and No E-lesions)

REGIMEN

DOSING

Doxorubicin + Bleomycin + Vinblastine + Dacarbazine (ABVD) (Category 1)2-5

Days 1 and 15: Doxorubicin 25mg/m2 IV push + bleomycin 10units/m2 IV push + vinblastine 6mg/m2 IV over 5–10 minutes + dacarbazine 375mg/m2 IV over 60 minutes.

Repeat cycle every 4 weeks for 2 cycles followed by radiation therapy.

ABVD (Preference to treat with chemotherapy alone)2-5

Days 1 and 15: Doxorubicin 25mg/m2 IV push + bleomycin 10units/m2 IV push + vinblastine 6mg/m2 IV over 5–10 minutes + dacarbazine 375mg/m2 IV over 60 minutes.

Repeat cycle every 4 weeks for 3 cycles.

ABVD (Preference to treat with combined modality therapy)2-5

Days 1 and 15: Doxorubicin 25mg/m2 IV push + bleomycin 10units/m2 IV push + vinblastine 6mg/m2 IV over 5–10 minutes + dacarbazine 375mg/m2 IV over 60 minutes.

Repeat cycle every 4 weeks for 2 cycles.

Doxorubicin + Vinblastine + Mechlorethamine + Etoposide + Vincristine + Bleomycin + Prednisone (Stanford V)6-9

Days 1 and 15: Doxorubicin 25mg/m2 IV push + vinblastine 6mg/m2 IV over 5–10 minutes

Day 1: Mechlorethamine 6mg/m2 IV push

Days 8 and 22: Vincristine 1.4mg/m2 (maximum 2mg) IV over 5–10 minutes + bleomycin 5units/m2 IV push

Days 15 and 16: Etoposide 60mg/m2 IV over 60 minutes

Days 1–28: Prednisone 40mg/m2 orally every other day. Taper prednisone dose by 10mg every other day beginning Day 15 of Cycle 2.

Repeat cycle every 4 week for 2 cycles followed by radiation therapy, optimally within 3 weeks of chemotherapy completion.

Stage I–II Unfavorable (Bulky or Non-bulky Disease)

Doxorubicin + Bleomycin + Vinblastine + Dacarbazine (ABVD)(Category 1 for Bulky Disease)2-5

Days 1 and 15: Doxorubicin 25mg/m2 IV push + bleomycin 10units/m2 IV push + vinblastine 6mg/m2 IV over 5–10 minutes + dacarbazine 375mg/m2 IV over 60 minutes.

Bulky or non-bulky disease: Repeat cycle every 4 weeks for 4-6 cycles total of ABVD or 4 cycles of AVD with or without subsequent radiation therapy (category 1 for bulky disease); or, for select patients younger than 60 years, repeat for 2 cycles, following 2 cycles of escalated BEACOPP, with or without subsequent radiation therapy.

Doxorubicin + Vinblastine + Mechlorethamine + Etoposide + Vincristine + Bleomycin + Prednisone (Stanford V)6-9

Days 1 and 15: Doxorubicin 25mg/m2 IV push + vinblastine 6mg/m2 IV over 5–10 minutes

Day 1: Mechlorethamine 6mg/m2 IV push

Days 8 and 22: Vincristine 1.4mg/m2 (maximum 2mg) IV over 5–10 minutes + bleomycin 5units/m2 IV push

Days 15 and 16: Etoposide 60mg/m2 IV over 60 minutes

Days 1–28: Prednisone 40mg/m2 orally every other day. Taper prednisone dose by 10mg every other day beginning Day 15 of Cycle 3.

Repeat cycle every 4 weeks for 3 cycles with or without subsequent radiation therapy.

Bleomycin + Etoposide + Doxorubicin + Cyclophosphamide + Vincristine + Procarbazine + Prednisone (Escalated BEACOPP) (In selected patients if IPS≥4, age <60)10,11

Day 1: Cyclophosphamide 1,250mg/m2 IV over 60 minutes + doxorubicin 35mg/m2 IV push

Days 1–3: Etoposide 200mg/m2 IV over 2 hours

Days 1–7: Procarbazine 100mg/m2 orally.

Day 8: Vincristine 1.4mg/m2 (maximum 2mg) IV over 5–10 minutes + bleomycin 10units/m2 IV push.

Days 1–14: Prednisone 40mg/m2 orally daily.

Repeat cycle every 3 weeks for 2 cycles followed by ABVD for 2 cycles and then by radiation therapy.

Stage III–IV

Doxorubicin + Bleomycin + Vinblastine + Dacarbazine (ABVD)2-5

Days 1 and 15: Doxorubicin 25mg/m2 IV push + bleomycin 10units/m2 IV push + vinblastine 6mg/m2 IV over 5–10 minutes + dacarbazine 375mg/m2 IV over 60 minutes.

Repeat cycle every 4 weeks for 2 cycles followed by 4 cycles of AVD or 4 cycles of escalated BEACOPP, cycles with or without subsequent radiation.

Doxorubicin + Vinblastine + Mechlorethamine + Etoposide + Vincristine + Bleomycin + Prednisone (Stanford V) (In selected patients if IPS 3)6-9

Days 1 and 15: Doxorubicin 25mg/m2 IV push + vinblastine 6mg/m2 IV over 5–10 minutes

Day 1: Mechlorethamine 6mg/m2 IV push

Days 8 and 22: Vincristine 1.4mg/m2 (maximum 2mg) IV over 5–10 minutes + bleomycin 5units/m2 IV push

Days 15 and 16: Etoposide 60mg/m2 IV over 60 minutes

Days 1–28: Prednisone 40mg/m2 orally every other day. Taper prednisone dose by 10mg every other day beginning Day 15 of Cycle 3.

Repeat cycle every 4 weeks for 3 cycles with or without subsequent radiation therapy.

Bleomycin + Etoposide + Doxorubicin + Cyclophosphamide + Vincristine + Procarbazine + Prednisone (Escalated BEACOPP) (In selected patients if IPS≥4, age <60)10,11

Day 1: Cyclophosphamide 1,250mg/m2 IV over 60 minutes + doxorubicin 35mg/m2 IV push

Days 1–3: Etoposide 200mg/m2 IV over 2 hours

Days 1–7: Procarbazine 100mg/m2 orally daily.

Day 8: Vincristine 1.4mg/m2 (maximum 2mg) IV over 5–10 minutes + bleomycin 10units/m2 IV push.

Days 1–14: Prednisone 40mg/m2 orally daily.

Repeat cycle in selected patients (IPS≥4, aged <60 years) every 3 weeks for 6 cycles, with or without subsequent radiation therapy.

Brentuximab Vedotin + Doxorubicin + Vinblastine + Dacarbazine (BV + AVD)12 (Category 2B)(Category 2A in select patients if IPS>4, bleomycin contraindicated, no known neuropathy)

Days 1 and 15: Brentuximab vedotin 1.2mg/kg IV over 30 minutes + doxorubicin 25mg/m2 IV push + vinblastine 6mg/m2 IV over 5–10 minutes + dacarbazine 375mg/m2 IV over 60 minutes.

Repeat cycle every 4 weeks for up to 2 cycles.

Second-line Systemic Therapy Options1

Note: No data have established the superiority of any of the subsequent chemotherapy options, and NCCN guidelines recommend an individualized approach.

Brentuximab vedotin22 (Alone or in combination with the second-line regimens below)

Day 1: Brentuximab 1.8mg/kg (maximum 180mg) IV over 30 minutes; for patients with hepatic impairment: 1.2mg/kg (up to 120mg).

Repeat cycle every 3 weeks until disease progression or unacceptable toxicity.

Dexamethasone + Cytarabine + Cisplatin (DHAP)23,24

Days 1–4: Dexamethasone 40mg orally or IV daily

Day 1: Cisplatin 100mg/m2 IV continuous infusion over 24 hours

Day 2: Cytarabine 2,000mg/m2 IV over 3 hours every 12 hours.

Repeat cycle every 3 to 4 weeks for 2–4 cycles (transplant candidates) or 4–8 cycles (nontransplant candidates).

Etoposide + Methylprednisolone + Cytarabine + Cisplatin (ESHAP)25–27

Days 1–4: Etoposide 40mg/m2 IV over 60 minutes + methylprednisolone 500mg IV over 15 minutes + cisplatin 25mg/m2 continuous IV infusion over 24 hours

Day 5: Cytarabine 2,000mg/m2 IV over 3 hours.

Repeat cycle every 3–4 weeks for 2–4 cycles (transplant candidates) or 4–8 cycles (nontransplant candidates).

Gemcitabine + Bendamustine + Vinorelbine (BeGEV)28

Day 1: Vinorelbine 20mg/m2 IV

Days 1 and 4: Gemcitabine 800mg/m2 IV

Days 2 and 3: Bendamustine 90mg/m2 IV.

Repeat cycle every 3 weeks for 4 cycles.

Gemcitabine + Vinorelbine + Pegylated liposomal doxorubicin (GVD)29

For transplant-naive patients:

Days 1 and 8: Gemcitabine 1,000mg/m2 IV over 30 minutes + vinorelbine 20mg/m2 IV over 5–10 minutes + pegylated liposomal doxorubicin 15mg/m2 IV over 60 minutes.

Repeat cycle every 3 weeks for 2–4 cycles (transplant candidates) or 4–8 cycles (nontransplant candidates).

For post-transplant patients:

Days 1 and 8: Gemcitabine 800mg/m2 IV over 30 minutes + vinorelbine 15mg/m2 IV over 5–10 minutes + pegylated liposomal doxorubicin 10mg/m2 IV over 60 minutes.

Repeat cycle every 3 weeks for 2–4 cycles (transplant candidates) or 4–8 cycles (nontransplant candidates).

Ifosfamide + Carboplatin + Etoposide (ICE)30,31

Days 1–3: Etoposide 100mg/m2 IV over 60 minutes

Day 2: Carboplatin AUC 5mg min/mL (max 800mg) IV + ifosfamide 5,000mg/m2 IV + mesna 5,000mg/m2 IV administered concurrently as a continuous infusion over 24 hours.

Repeat cycle every 2–3 weeks for 2–4 cycles (transplant candidates) or 4–8 cycles (nontransplant candidates).

Ifosfamide + Gemcitabine + Vinorelbine (IGEV)32

Days 1–4: Ifosfamide 200mg/m2 IV over 2 hours plus mesna 2,600mg/m2 IV

Days 1 and 4: Gemcitabine 800mg/m2 IV over 30 minutes

Day 1: Vinorelbine 20mg/m2 IV over 5–10 minutes

Days 1–4: Prednisone 100mg PO daily.

Repeat cycle every 3 weeks for 2–4 cycles (transplant candidates) or 4–8 cycles (nontransplant candidates).

Subsequent Systemic Therapy Options

Bendamustine33

Days 1 and 2: Bendamustine 70–120mg/m2 IV over 30 minutes.

Repeat cycle every 4 weeks until maximal response or unacceptable toxicity.

Cyclophosphamide + Vincristine + Procarbazine + Prednisone (C-MOPP) (Category 2B)1

Day 1: Cyclophosphamide 650mg/m2 IV over 30 minutes + vincristine 1.4mg/m2 (maximum 2mg) IV

Days 1–7: Procarbazine 100mg/m2 orally daily

Days 1–14: Prednisone 40mg/m2 orally daily.

Repeat cycle every 4 weeks for 4–8 cycles.

OR

Days 1 and 8: Cyclophosphamide 500mg/m2 IV over 30 minutes + vincristine 1.4mg/m2 (maximum 2mg) IV over 5–10 minutes

Days 1–14: Procarbazine 100mg/m2 orally daily.

Days 1–3 and 8–10: Prednisone 40mg/m2 orally daily.

Repeat cycle every 4 weeks for 4–8 cycles.

Everolimus34

Everolimus 10mg orally daily until disease progression or unacceptable toxicity.

Gemcitabine + Carboplatin + Dexamethasone (GCD)35,36

Days 1 and 8: Gemcitabine 1000mg/m2 IV over 30 minutes

Day 1: Carboplatin AUC 5mg min/mL (maximum 800mg) IV over 60 minutes

Days 1–4: Dexamethasone 40mg orally daily.

Repeat cycle every 3 weeks for 2–4 cycles (transplant candidates) or 4–8 cycles (nontransplant candidates).

Lenalidomide37

Days 1–21: Lenalidomide 25mg orally daily.

Repeat cycle every 4 weeks until disease progression or unacceptable toxicity.

Carmustine + Cytarabine + Etoposide + Melphalan (Mini-BEAM)39,40

Day 1: Carmustine 60mg/m2 IV over 2 hours

Days 2–5: Etoposide 75mg/m2 IV over 60 minutes daily + cytarabine 100mg/m2 IV over 3 hours every 12 hours

Day 6: Melphalan 30mg/m2 IV over 15 minutes.

Repeat cycle every 4–6 weeks for 2–4 cycles.

Mitoxantrone + Ifosfamide + Mesna + Etoposide (MINE)38

Days 1–3: Mesna 1.33 g/m2 IV daily, and 500 mg PO daily 4 hours after each IV dose plus ifosfamide 1.33 g/m2 IV daily, given concurrently with mesna, for 3 days.

Day 1: Mitoxantrone 8mg/m2 IV over 30 minutes.

Repeat cycle every 3 weeks for 2–4 cycles (transplant candidates) or 4–8 cycles (nontransplant candidates).

Nivolumab41,42,a

Nivolumab 3mg/kg IV every 2 weeks until disease progression or unacceptable toxicity.

Pembrolizumab43,a

Pembrolizumab 10mg/kg IV every 2 weeks until disease progression or unacceptable toxicity.

Maintenance Therapy

Brentuximab vedotin44

Day 1: Brentuximab 1.8mg/kg (maximum 180mg) IV over 30 minutes. Repeat cycle every 3 weeks until disease progression or unacceptable toxicity for a maximum of 1 year after HDT/SCR (if primary refractory disease or relapse occurred <12 months after primary therapy).

Nodular Lymphocyte-Predominant Hodgkin Lymphoma1

Primary Treatment

Doxorubicin + Bleomycin + Vinblastine + Dacarbazine (ABVD) ± Rituximab13,14

Days 1 and 15: Doxorubicin 25mg/m2 IV push + bleomycin 10units/m2 IV push + vinblastine 6mg/m2 IV over 5–10 minutes + dacarbazine 375mg/m2 IV over 60 minutes, ±

Day 1: Rituximab 375mg/m2 IV for all cycles.

OR

Days 1, 8, 15, and 22: Rituximab 375mg/m2 IV for cycle 1 only.

Repeat cycle every 4 weeks for 3-4 cycles with subsequent radiation or 6-8 cycles without subsequent radiation.

Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) ± Rituximab15

Day 1: Cyclophosphamide 750mg/m2 over 60 minutes + doxorubicin 50mg/m2 IV push + vincristine 1.4mg/m2 (maximum 2mg) IV over 5–10 minutes

Days 1–5: Prednisone 100mg orally daily, ±

Day 1: Rituximab 375mg/m2 IV.

Repeat cycle every 3 weeks for 3-4 cycles with subsequent radiation or 6-8 cycles without subsequent radiation.

Cyclophosphamide + Vincristine + Prednisone (CVP) ± Rituximab16

Day 1: Cyclophosphamide 750mg/m2 OR 1,000mg/m2 over 60 minutes + vincristine 1.4mg/m2 (maximum 2mg) IV over 5–10 minutes

Days 1–5: Prednisone 100mg orally daily, ±

Day 1: Rituximab 375mg/m2 IV.

Repeat cycle every 3 weeks for 3-4 cycles with subsequent radiation or 6 cycles without subsequent radiation.

Rituximab17–21

Day 1: Rituximab 375mg/m2 IV.

Repeat cycle every 7 days for 4 weeks with or without maintenance rituximab (375mg/m2 IV once weekly for 4 weeks every 6 months for up to 2 years).

Second-line Systemic Therapy Options1

Dexamethasone + Cytarabine + Cisplatin (DHAP)15,16

Days 1–4: Dexamethasone 40mg orally or IV daily

Day 1: Cisplatin 100mg/m2 IV continuous infusion over 24 hours

Day 2: Cytarabine 2,000mg/m2 IV over 3 hours every 12 hours.

Repeat cycle every 3 to 4 weeks for 2–4 cycles (transplant candidates) or 4–8 cycles (nontransplant candidates).

Etoposide + Methylprednisolone + Cytarabine + Cisplatin (ESHAP)17,18

Days 1–4: Etoposide 40mg/m2 IV over 60 minutes + methylprednisolone 500mg IV over 15 minutes + cisplatin 25mg/m2 continuous IV infusion over 24 hours

Day 5: Cytarabine 2,000mg/m2 IV over 3 hours.

Repeat cycle every 3–4 weeks for 2–4 cycles (transplant candidates) or 4–8 cycles (nontransplant candidates).

Ifosfamide + Carboplatin + Etoposide (ICE)16,21

Days 1–3: Etoposide 100mg/m2 IV over 60 minutes

Day 2: Carboplatin AUC 5mg min/mL (max 800mg) IV + ifosfamide 5,000mg/m2 IV + mesna 5,000mg/m2 IV administered concurrently as a continuous infusion over 24 hours.

Repeat cycle every 2–3 weeks for 2–4 cycles (transplant candidates) or 4–8 cycles (nontransplant candidates).

Ifosfamide + Gemcitabine + Vinorelbine (IGEV)22

Days 1–4: Ifosfamide 200mg/m2 IV over 2 hours plus mesna 2,600mg/m2 IV

Days 1 and 4: Gemcitabine 800mg/m2 IV over 30 minutes

Day 1: Vinorelbine 20mg/m2 IV over 5–10 minutes

Days 1–4: Prednisone 100mg PO daily.

Repeat cycle every 3 weeks for 2–4 cycles (transplant candidates) or 4–8 cycles (nontransplant candidates).

a Checkpoint inhibitors (CPI) are commonly recommended for patients with refractory CHL who are transplant-ineligible based on comorbidity or failure of first salvage chemotherapy, and any patient who has relapsed after autologous HSCT+brentuximab vedotin. Nivolumab or pembrolizumab can be administered to patients post-allogeneic transplant; there is limited data regarding the use of CPI following allogeneic transplantation. Caution is advised due to increased risk of GVHD (graft-versus-host disease) and other immunological complications.

References

1. NCCN Clinical Practice Guidelines in Oncology™. Hodgkin Lymphoma.V.3.2018.Available at: http://www.nccn.org/ professionals/physician_gls/pdf/hodgkins.pdf. Accessed April 12, 2018.

2. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363:640–652.

3. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015;372:1598-1607.

4. Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography–negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32:1188-1194.

5. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD 11 trial. J Clin Oncol. 2010;28:4199-4206.

6. Advani RH, Hoppe RT, Baer D, et al. Efficacy of abbreviated Stanford V chemotherapy and involved- eld radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. Ann Oncol. 2013;24:1044-1048.

7. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013; 31:684-691.

8. Advani RH, Hong F, Fisher RI, et al. Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin hymphoma: a subset analysis of the north american Intergroup E2496 trial. J Clin Oncol. 2015;33: 1936-1942.

9. Edwards-Bennett SM, Jacks LM, Moskowitz CH, et al. Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Ann Oncol. 2010;21:574–581.

10. Engert A, Haverkamp H, Cobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012; 379(9828):1791-1799.

11. von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012:30:907-913.

12. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018; 378(4):331-344.

13. Savage KJ, Skinnider B, Al-Mansour M, et al. Treating limited stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood. 2011;118:4585-4590.

14. Canellos GP, Mauch P. What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's Lymphoma? J Clin Oncol. 2010;28:e8.

15. Fanale MA, Cheah CY, Rich A, et al. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017;130:472- 477.

16. Shankar A, Hall GW, Gorde-Grosjean S, et al. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report. Eur J Cancer. 2012;48:1700-1706.

17. Advani RH, Hoppe RT. How I treat nodular lymphocyte predominant Hodgkin lymphoma. Blood. 2013;122:4182-4188.

18. Advani RH, Horning SJ, Hoppe RT, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2014;32:912-918.

19. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111(1):109-111.

20. Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011;118:4363-4365.

21. Eichenauer DA, Plutschow A, Fuchs M, et al. Long-Term Course of Patients With Stage IA Nodular Lymphocyte- Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. J Clin Oncol. 2015;33:2857-2862.

22. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30:2183- 2189.

23. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol. 2002;13(10):1628-1635.

24. Abali H, Urün Y, Oksüzoglu B, Budakoglu B, et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest. 2008;26(4):401-406.

25. Aparicio J, Segura A, Garcera S, et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol. 1999;10(5):593-595.

26. Fernández de Larrea C, Martínez C, et al. Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem cell transplantation. Ann Oncol. 2010;21(6):1211-1216.

27. Labrador J, Cabrero-Calvo M, Perez-Lopez E, et al. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. Ann Hematol. 2014;93:1745-1753.

28. Santoro A, Mazza R, Pulsoni A, et al. Bendamustine in combination with gemcitabine and vinorelbine is an e ective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study. J Clin Oncol. 2016;34:3293-3299.

29. Bartlett N, Niedzwiecki D, Johnson J, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007;18(6):1071-1079.

30. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hogdkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001; 97(3):616–623.

31. Abali H, Urün Y, Oksüzoglu B, Budakoglu B, et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest. 2008;26(4):401-406.

32. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica. 2007;92(1):35-41.

33. Moskowitz AJ, Hamlin PA, Perales M-A, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31:456-460.

34. Johnston PB, Inwards DJ, Colgan JP, et al; A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85(5):320-324.

35. Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32:3490-3496.

36. Gopal AK, Press OW, Shustov AR, et al. Effcacy and safety of gemicitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by Puget Sound Oncology Consortium. Leuk Lymphoma. 2010;51:1523-1529.

37. Fehniger TA, Larson S, Trinkaus K, et al; A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011;118(19):5119-25.

38. Rodriguez MA, Cabanillas FC, Hagemeister FB, et al. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphoma. Ann Oncol. 1995;6(6):609-611.

39. Colwill R, Crump M, Couture F, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol. 1995;13:396-402.

40. Martín A, Fernández-Jiménez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol. 2001;113(1):161-171.

41. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311-319.

42. Timmerman J, Armand P, Lesokhin AM, et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: Updated results of a phase 1 study (CA 209-039) [abstract]. Hematol Oncol. 2015;33:Abstract 010.

43. Armand P, Shipp MA, Ribrag V, et al. Programmed Death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016; 34(31):3733-3739.

44. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as a consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980)1853–1862.


Hematologic Cancer Drug Monographs

Leukemias, Lymphomas, And Other Hematologic Cancers

ADCETRIS ALKERAN ALKERAN FOR INJECTION
ARRANON ARZERRA BELEODAQ
BENDEKA BEXXAR BICNU
BLEOMYCIN BLINCYTO BOSULIF
BUSULFEX CAMPATH CERUBIDINE
CLADRIBINE CLOLAR CYCLOPHOSPHAMIDE
CYTARABINE CYTOXAN INJECTION DACOGEN
DARZALEX DEPOCYT DOXIL
DOXORUBICIN HCL DOXORUBICIN HCL SOLUTION DTIC-DOME
EMPLICITI ERWINAZE EVOMELA
FARYDAK FLUDARA FOLOTYN
GAZYVA GLEEVEC GLEOSTINE
HYDREA ICLUSIG IDAMYCIN
IDAMYCIN PFS IMBRUVICA INTRON A
INTRON A SOLN ISTODAX JAKAFI
KEYTRUDA KYPROLIS LEUKERAN
MARQIBO MATULANE METHOTREXATE FOR INJECTION
METHOTREXATE INJECTION MITOXANTRONE HCL MUSTARGEN
MYLERAN NINLARO ONCASPAR
ONTAK OPDIVO PAMIDRONATE DISODIUM INJECTION
PENTOSTATIN POMALYST PURINETHOL
PURIXAN REVLIMID RITUXAN
SPRYCEL SYNRIBO TABLOID
TARGRETIN TARGRETIN GEL TASIGNA
THALOMID TREANDA TREXALL
TRISENOX UVADEX VALCHLOR
VELCADE VENCLEXTA VESANOID
VIDAZA VINBLASTINE FOR INJECTION VINBLASTINE INJECTION
VINCASAR PFS VUMON ZEVALIN
ZOLINZA ZOMETA ZYDELIG

Data provided by the Monthly Prescribing Reference (MPR) Hematology/Oncology Edition.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs